Brokers Issue Forecasts for Zoetis’ Q2 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of Zoetis in a note issued to investors on Monday, May 26th. Zacks Research analyst E. Bagri now expects that the company will earn $1.59 per share for the quarter, down from their previous forecast of $1.60. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q1 2027 earnings at $1.66 EPS and FY2027 earnings at $7.25 EPS.

A number of other research firms also recently issued reports on ZTS. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $212.75.

Zoetis Stock Performance

NYSE ZTS opened at $166.23 on Wednesday. Zoetis has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a fifty day moving average price of $156.53 and a 200-day moving average price of $164.69. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market cap of $74.01 billion, a price-to-earnings ratio of 30.39, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the business posted $1.38 EPS. The business’s revenue was up 1.4% compared to the same quarter last year.

Institutional Investors Weigh In On Zoetis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares in the last quarter. Geode Capital Management LLC raised its stake in Zoetis by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC raised its stake in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by company insiders.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.